These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12380043)

  • 21. Safety of droperidol in behavioural emergencies.
    Shale JH; Shale CM; Mastin WD
    Expert Opin Drug Saf; 2004 Jul; 3(4):369-78. PubMed ID: 15268653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Droperidol: should the black box be light gray?
    Dershwitz M
    J Clin Anesth; 2002 Dec; 14(8):598-603. PubMed ID: 12565120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does low-dose droperidol increase the risk of polymorphic ventricular tachycardia or death in the surgical patient?
    Nuttall GA; Malone AM; Michels CA; Trudell LC; Renk TD; Marienau ME; Oliver WC; Ackerman MJ
    Anesthesiology; 2013 Feb; 118(2):382-6. PubMed ID: 23291623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reviewing case reports and the droperidol warning: FDA response.
    Chang N; Simone A; Schultheis L; Rappaport B
    Anesth Analg; 2003 Nov; 97(5):1542. PubMed ID: 14570686
    [No Abstract]   [Full Text] [Related]  

  • 25. [Long QT syndrome].
    Zbinden S
    Anaesthesist; 2006 Sep; 55(9):1006-7; author reply 1007-8. PubMed ID: 16897019
    [No Abstract]   [Full Text] [Related]  

  • 26. "Black Box" warning labels and drug withdrawals.
    Thomas JA
    Toxicol Appl Pharmacol; 2002 Sep; 183(2):81. PubMed ID: 12387746
    [No Abstract]   [Full Text] [Related]  

  • 27. Droperidol and the black box warning.
    van Zwieten K; Mullins ME; Jang T
    Ann Emerg Med; 2004 Jan; 43(1):139-40. PubMed ID: 15259182
    [No Abstract]   [Full Text] [Related]  

  • 28. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified?
    Gan TJ; White PF; Scuderi PE; Watcha MF; Kovac A
    Anesthesiology; 2002 Jul; 97(1):287. PubMed ID: 12131145
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse-drug-reaction monitoring.
    Faich GA
    N Engl J Med; 1986 Jun; 314(24):1589-92. PubMed ID: 3713757
    [No Abstract]   [Full Text] [Related]  

  • 31. Adverse drug reaction reporting.
    Bosco LA
    Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
    [No Abstract]   [Full Text] [Related]  

  • 32. Food and drug administration black box warning on the perioperative use of droperidol: a review of the cases.
    Habib AS; Gan TJ
    Anesth Analg; 2003 May; 96(5):1377-1379. PubMed ID: 12707137
    [No Abstract]   [Full Text] [Related]  

  • 33. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 34. Low-dose droperidol.
    Allen G
    CMAJ; 2002 Sep; 167(5):452; author reply 452. PubMed ID: 12240805
    [No Abstract]   [Full Text] [Related]  

  • 35. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 36. There should be a threshold dose for the FDA black-box warning on droperidol.
    Habib AS; Gan TJ
    Anesth Analg; 2003 Nov; 97(5):1543. PubMed ID: 14570685
    [No Abstract]   [Full Text] [Related]  

  • 37. News flash: Old Mother Hubbard reports the cupboard is bare...time for the FDA to let droperidol out of the (black) box.
    Faine B; Hogrefe C
    Ann Pharmacother; 2012 Sep; 46(9):1259-61. PubMed ID: 22828973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-induced prolongation of the QT interval: what's the point?
    White PF; Abrao J
    Anesthesiology; 2006 Feb; 104(2):386-7. PubMed ID: 16436877
    [No Abstract]   [Full Text] [Related]  

  • 39. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 40. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.